Anti-clostridial role of probiotics in prevention and treatment of clostridium difficile infections

Shahrbanoo Asgarian,1,*

1. Tarbiat Modares University, Faculty of Medical Sciences, Department of Bacteriology



Patients with varied conditions, such as antibacterial therapy, cancer chemotherapy, and gastrointestinal surgery are at greater risk of acquiring clostridium difficult infections. primary treatments for this infection are metronidazole, fidaxomicin, and vancomycin. the problem is that this infection returns in patients. fecal microbiota transplanting from a healthy person to the colon of a patient appears to be the most effective method of treatment. this procedure could not be widely available and its safety has not yet been established.


The present study was conducted to identify studies focused on the use of probiotics for the prevention and treatment of cdi in hospitalized patients by searching the biomedical electronic databases such as ovid medline, the cochrane library, ovid embase, google scholar, pubmed and the international journal of probiotics. one reviewer identified the studies and abstracted database on sample size, treatments, population characters, and outcomes.


Most of the evidence has suggested that probiotics have a key role in primary prevention of cdi. the proposed mechanisms of action on prevention and treatment, the ineffectiveness of probiotics are addressed with a focus on three microorganisms, saccharomyces boulardii, lactobacillus rhamnosus gg and the combination of lactobacillus casei lbc80r, lactobacillus rhamnosus clr2, and lactobacillus acidophilus cl1285.


These results and recent successes in fecal microbiota transplants in cdi treatment are supportive for the rational design of multi-strain lactobacilli because their efficacy is strain-specific. future research should focus on optimal probiotic dose, other species, and drug formulation.


Lactobacillus, clostridium difficile, fecal microbiota